Weinreb, Caleb
Pearl, Jonah E. http://orcid.org/0000-0001-9300-1552
Lin, Sherry http://orcid.org/0000-0002-1275-8391
Osman, Mohammed Abdal Monium http://orcid.org/0000-0001-8606-6518
Zhang, Libby http://orcid.org/0000-0003-2069-4081
Annapragada, Sidharth
Conlin, Eli
Hoffmann, Red
Makowska, Sofia
Gillis, Winthrop F.
Jay, Maya
Ye, Shaokai http://orcid.org/0000-0003-4250-2220
Mathis, Alexander http://orcid.org/0000-0002-3777-2202
Mathis, Mackenzie W. http://orcid.org/0000-0001-7368-4456
Pereira, Talmo http://orcid.org/0000-0001-9075-8365
Linderman, Scott W. http://orcid.org/0000-0002-3878-9073
Datta, Sandeep Robert http://orcid.org/0000-0002-8068-3862
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (RF1AG073625, R01NS114020, U24NS109520, F31NS113385, F31NS122155)
Article History
Received: 5 April 2023
Accepted: 22 May 2024
First Online: 12 July 2024
Competing interests
: S.R.D. sits on the scientific advisory boards of Neumora and Gilgamesh Therapeutics, which have licensed or sub-licensed the MoSeq technology. The other authors declare no competing interests.